BEACON CRC: A randomized, phase 3 study of encorafenib (ENCO) and cetuximab (CETUX) with or without binimetinib (BiNI) vs. choice of either irinotecan or folfiri plus cetux in BRAF V600E-mutant metastatic colorectal cancer (mCRC) Meeting Abstract
| Authors: | Vogel, A.; Hegewisch-Becker, S.; Prager, G.; Folprecht, G.; Stahl, M.; Kopetz, S.; Grothey, A.; van Cutsetn, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardello, F.; Gollerkeri, A.; Maharry, K.; Loupakis, F.; Hong, Y.; Steeghs, N.; Guren, T. K.; Arkenau, H. T.; Garcia-Alfons, P.; Sandor, V.; Christy-Bittel, F.; Anderson, L.; Tabernero, J. |
| Abstract Title: | BEACON CRC: A randomized, phase 3 study of encorafenib (ENCO) and cetuximab (CETUX) with or without binimetinib (BiNI) vs. choice of either irinotecan or folfiri plus cetux in BRAF V600E-mutant metastatic colorectal cancer (mCRC) |
| Meeting Title: | 34. Deutscher Krebskongress (DKK) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 43 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Feb 19-22 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2020-02-01 |
| Start Page: | 55 |
| Language: | English |
| ACCESSION: | WOS:000517158700138 |
| PROVIDER: | wos |
| DOI: | 10.1159/000506491 |
| Notes: | "34th German Cancer Congress" -- Meeting Abstract: 608 -- Source: Wos |
